OLFM4 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, analysis of OLFM4 and its isoforms in peripheral blood could be exploited as predictive markers for treatment regimens, while targeting OLFM4 or OLFM4-mediated signaling could be explored as an option to eradicate primitive CML cells.